



Franklin Templeton Investment Funds

Franklin Biotechnology Discovery Fund

Fund Fact Sheet

Sector Equity
30.09.2025

For the source and calculation basis of Fund information, please refer to the *Explanatory Notes section.

Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	1.53 billion
Fund Inception Date	03.04.2000
Number of Issuers	80
Benchmark	NASDAQ Biotechnology Index
Morningstar Category™*	Sector Equity Biotechnology

Summary of Investment Objective

To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.

Fund Management*

Evan McCulloch, CFA: United States

Akiva Felt: United States

Ratings - A (acc) USD

Overall Morningstar Rating™*: ★★ ★

Asset Allocation*

	%
Equity	95.34
Cash & Cash Equivalents	4.66

Offering Documents



Shareholder Letters



Risk Considerations

INVESTMENT INVOLVES RISKS. The value of the Fund can be volatile and investors may not get back the amount originally invested. Past performance is not indicative of future results.

- Franklin Biotechnology Discovery Fund invests principally in equity securities issued by biotechnology companies in the U.S. and other countries.
- The Fund is subject to market risk, equity risk, foreign currency risk, liquidity risk, biotechnology, communication and technology sectors risk, debt securities risk, concentration risk, smaller and midsize companies risk, growth stocks risk, counterparty risk, Private Investments in Public Equity risk, private companies risk, special purpose acquisition companies risk and derivative instruments risk.
- Security lending transactions may involve the risk that the borrower may fail to return the securities lent out in a timely manner and the value of the collateral may fall below the value of the securities lent out, which may result in a substantial loss to the Fund.
- The Fund may at its discretion pay dividends out of the capital or out of gross income of the Fund while paying all or part of the Fund's fees and expenses out of the capital of the Fund, which results in effectively paying dividends out of capital. Payment of dividends out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any distributions involving payment of dividends out of the Fund's capital or payment of dividends effectively out of the Fund's capital (as the case may be) may result in an immediate reduction of the net asset value per share.
- Investors should not invest based on this marketing material alone. Offering documents should be read for further details, including the risk factors. Before you decide to invest, you should make sure the intermediary has explained to you that the Fund is suitable to you.

Performance*

Past performance does not predict future returns.

Performance over 5 Years in Share Class Currency (%)

■ Franklin Biotechnology Discovery Fund A (acc) USD



Performance in Share Class Currency (%)

	Cumulative						
	3 Mths	YTD	1 Yr	3 Yrs	5 Yrs	10 Yrs	Since Incept
A (acc) USD	28.71	22.44	8.66	57.92	17.73	60.03	380.55
Benchmark in USD	15.43	13.21	2.35	29.52	14.64	53.98	358.08

Calendar Year Performance in Share Class Currency (%)

	2024	2023	2022	2021	2020
A (acc) USD	2.64	17.29	-12.51	-17.36	27.52
Benchmark in USD	-1.37	3.74	-10.91	-0.63	25.69

Top Ten Holdings* (% of Total)

Issuer Name	
GILEAD SCIENCES INC	6.32
AMGEN INC	4.93
VERTEX PHARMACEUTICALS INC	4.82
ARGENX SE	4.31
ALNYLAM PHARMACEUTICALS INC	4.27
REGENERON PHARMACEUTICALS INC	3.98
JAZZ PHARMACEUTICALS PLC	3.83
UNIQUE NV	3.71
INSMED INC	3.34
ASCENDIS PHARMA A/S	3.11

Fund Measures

P/E to Growth	3.75x
Historical 3 Yr Sales Growth	24.71%
Estimated 3-5 Yr EPS Growth	4.80%
Price to Earnings (12-mo Forward)	18.50x
Standard Deviation (5 Yrs)	19.01%

For the source and calculation basis of Fund information, please refer to the *Explanatory Notes section.

Share Class Information

Share Class	Incept Date	NAV	Fees			Dividends		Fund Identifiers
			Max. Sales Charge (%)	Max. Annual Charge* (%)	Max. Serv. Charge (%)	Last Paid Date	Last Paid Amount	ISIN
A (acc) USD	03.04.2000	USD 48.06	5.00	1.50	N/A	N/A	N/A	LU0109394709
A (acc) HKD	26.02.2013	HKD 31.17	5.00	1.50	N/A	N/A	N/A	LU0889565916

The charges are the fees the fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund.

Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Composition of Fund*

Market Capitalisation Breakdown in USD	% of Equity
<2.0 Billion	21.52
2.0-5.0 Billion	20.57
5.0-10.0 Billion	13.11
10.0-25.0 Billion	6.30
25.0-50.0 Billion	8.67
>50.0 Billion	29.35
N/A	0.48

Important Information

Unless stated otherwise, all information is as of the publishing date of this document. Source: Franklin Templeton.

Copyright © 2025. Franklin Templeton. All rights reserved.

Franklin Templeton Investments (Asia) Limited is the issuer of this document. This document is for information only and nothing contained herein constitutes investment advice. All charts, data, opinions, estimates and other information are provided as of the date of this document and may be subject to change without notice. This document is neither an offer nor solicitation to purchase shares of the fund. **Investment involves risks, fund value may go up as well as down and past performance is not an indicator or a guarantee of future performance.** The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD ("other foreign currency"). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

Any share class with "H1" in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

In addition, a summary of investor rights is available from <https://www.franklintempleton.com.hk/en-hk/about-us/summary-of-investor-rights>. The summary is available in English and Chinese.

The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/sub-fund(s).

Distribution of this document may be restricted in certain jurisdictions. This document does not constitute the distribution of any information or the making of any offer or solicitation by anyone in any jurisdiction in which such distribution or offer is not authorized or to any person to whom it is unlawful to distribute such a report or make such an offer or solicitation. Any person coming into possession of this document should seek advice for details of, and observe, such restrictions (if any). This document has not been reviewed by the Securities and Futures Commission of Hong Kong.

*Explanatory Notes

Performance: Performance information is based on the stated share class only, in Fund Currency, NAV to NAV, taking into account of dividend reinvestments and capital gain or loss. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Morningstar Category™: Copyright © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Past performance is not an indicator or a guarantee of future performance.

Fund Management: In the case of portfolio managers who are CFA Charterholders, CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Ratings: Copyright © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Past performance is not an indicator or a guarantee of future performance.

Top 10 Holdings: These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable.

Asset Allocation/Composition of Fund: Due to rounding, the sum of portfolio may not equal 100%.

Fees: Maximum Annual Charge includes Management Fee and Maximum Maintenance Charge.